Glaucoma, "a silent thief of sight" and the leading cause of irreversible blindness, is characterized by retinal ganglion cell (RGC) death and optic nerve degeneration. Elevation of intraocular pressure (IOP), also called ocular hypertension, is the most recognized risk factor for glaucoma (Jonas et al., 2017). Current therapies only target reduction of IOP, but irreversible RGC death continues even after IOP is normalized (Wormald et al., 2020), indicating the critical clinical need to prevent degeneration and/or replace lost RGCs. Deciphering the key molecular mechanisms of glaucomatous degeneration and identifying or testing novel therapeutic targets for neuroprotection and regeneration, requires reliable, reproducible, and reversible ocular hypertension/glaucoma models in experimental animals. Due to the similarity of its anatomical structure and aqueous humor dynamics to those of the human eye, its strong reproductive ability, genetic plasticity, well developed transgenic techniques, and low price, the mouse has been used extensively to model glaucoma. While genetic mouse models are valuable to understand the roles of a specific gene in IOP elevation and/or glaucomatous neurodegeneration, the pathologic effects of a mutation may not manifest for months or even years (Libby et al., 2005; Chi et al., 2010). Inducible ocular hypertension that develops more quickly and is more severe is preferable for testing experimental manipulations and studying neurodegeneration mechanism associated with IOP elevation.

IOP rises or falls in response to two processes: aqueous inflow to the anterior chamber through the pupil from the ciliary body in the posterior chamber and aqueous outflow through the trabecular meshwork (TM) at the angle of the anterior chamber. After traversing the TM, the aqueous is collected into the limbal venous plexus via collector channels and finally flows into the episcleral veins to enter the blood circulation. When aqueous inflow and outflow reach a steady state, normal IOP is maintained; when aqueous inflow exceeds outflow, IOP rises; when aqueous outflow exceeds inflow, IOP falls. Almost all of the previous inducible glaucoma models increase IOP by decreasing aqueous outflow, either through occluding the angle of the anterior chamber or by damaging the TM. These models are excellently summarized in a recent comprehensive review (Pang and Clark, 2019). We recently developed an inducible ocular hypertension model in mice by preventing aqueous inflow into the anterior chamber (Zhang et al., 2019a, b). Here we compare our new model to several common inducible mouse models of ocular hypertension, and briefly summarize the unique features, major drawbacks and potential applications of these models in basic and preclinical research.

Ocular hypertension and glaucomatous neurodegeneration induced by intracameral injection of silicone oil (SO): SO is used as a tamponade in retinal detachment repair surgery because it is buoyant with high surface tension. However, SO is lighter than the aqueous and vitreous fluids and an excess can physically occlude the pupil, which in turn prevents aqueous flow into the anterior chamber. This obstruction leads to a post-operative complication with increased aqueous pressure in the posterior chamber and anterior displacement of the iris, which causes angle-closure, blockage of aqueous outflow through TM, and a further increase in IOP (Ichhpujani et al., 2009). We recently faithfully replicated this well-documented, human secondary glaucoma in mouse eyes by intracameral injection of SO (Zhang et al., 2019a, b). SO injected into anterior chamber effectively blocks the pupil, which thwarts aqueous inflow. Aqueous humor, which is constantly produced by the ciliary body, accumulates in the posterior chamber and consequently increases the IOP of the posterior segment. When the iris is pushed forward and the iris root touches the posterior corneal surface, the anterior chamber angle closes. The angle closure further impedes the outflow of aqueous humor through TM and also contributes to IOP elevation. Thus, by mimicking this human secondary glaucoma, we create a novel ocular hypertension model in mice with confined aqueous accumulation in the posterior chamber and elevated IOP of the posterior segment.

In contrast to the SO model, intracameral injection of polystyrene microbeads physically obstruct aqueous outflow by accumulating and occluding the TM and Schlemm's canal (Sappington et al., 2010). Refinements of this basic technique include adding viscoelastic material or replacing polystyrene microbeads with magnetic microbeads (Pang and Clark, 2019). Despite mixed success between labs in reproducing the microbead model, the microbeads model has become popular and contributed to many significant novel findings in glaucoma research. Compared with the acute IOP elevation in the SO model, microbeads injection increases IOP more slowly and mildly, which may more closely resemble chronic glaucoma in the clinic. A caveat is the relatively modest neurodegeneration in this mouse model, which leaves a narrow window for preclinical testing of neuroprotective therapies. Another important caveat to its use, however, is that it is challenging to retain microbeads at the angle of the anterior chamber and to control the degree of aqueous outflow blockade. In order to maintain a long duration of elevated IOP at the necessary level to cause RGC loss, reinjection is normally required, which increases complications such as corneal opacity, neovascularization, and ulceration, as well as endophthalmitis.

Another common method to decrease aqueous outflow is to use a diode laser to photocoagulate the outflow structures, the TM, limbal plexus or episcleral veins; damage of these structures closes intertrabecular spaces and major outflow channels and thus increases the resistance of the outflow pathway (Pang and Clark, 2019). This method needs expensive ophthalmic laser equipment and highly specialized skills, as well as multiple repeats of the procedures to increase the chance of IOP elevation. It is also more successful in large animals, such as non-human primate, because it is difficult to apply to the small mouse eye. Laser photocoagulation in mouse eye is normally associated with relatively severe complications, including permanent and extensive sclera damage, outer retina injuries, intraocular inflammation, and retinal and choroidal ischemia. Compared to this model, the SO model is much simpler, more stable, and, importantly, undoubtedly much less damaging to the eye. Since SO causes ocular hypertension in both human patients and mice, it is reasonable to hypothesize that the same procedure may be adapted to different animal species with minimal confounding factors. The anatomy of the non-human primate visual system closely resembles that of humans and includes a macula and lamina cribrosa not present in mouse. An non-human primate SO glaucoma model is the most likely to predict human responses to ocular hypertension and therapies.

Similar to the SO model, which mimics clinical secondary glaucoma in human, topical ocular administration of the glucocorticoid, dexamethasone, in mice also replicates human secondary glaucoma and induces ocular hypertension and glaucomatous neurodegeneration (Zode et al., 2014). Glucocorticoids are commonly used to treat ocular inflammation. However, for reasons that are not well understood, prolonged treatment with glucocorticoids causes IOP elevation and secondary open angle glaucoma in about 30% of patients (Fini et al., 2017). Although there is evidence to support the role of glucocorticoids in TM dysfunction and IOP elevation in mice (Pang and Clark, 2019), the multiple systemic functions of glucocorticoids complicate interpreting the pathogenesis of glucocorticoid-induced glaucomatous neurodegeneration.

Compared to these commonly used ocular hypertension and glaucoma mouse models, the SO model has some advantages that we summarize in **[Table 1](#T1){ref-type="table"}**: 1) A single SO injection into anterior chamber allows a reliable, sufficient, and stable IOP elevation without the multiple treatments required by other models. 2) The size of the SO droplet stays stable for a long period and also correlates well with IOP elevation; unresponsive animals can be predicted by the size of the SO droplet very soon after injection and excluded promptly. 3) RGC and optic nerve degeneration is consistent and progressive, and the degeneration correlates well with imaging and visual function deficits similar to those observed in patients. 4) Because the unique pathogenesis of the pupillary block spares the ocular elements in the anterior part of the eye from damage by high IOP, the clear cornea, lens and transparent SO allow light to the retina for *in vivo* assessment of visual function and morphology. 5) Because SO injection does not permanently damage ocular tissues and the SO can be removed easily to lower IOP quickly to normal, another unique feature of this model is that the ocular hypertension is reversible. Thus, it can mimic the clinical setting and test whether lowering IOP together with neuroprotection, regeneration, or cell replacement therapies provides additional benefits for visual function recovery.

###### 

Comparison of inducible ocular hypertension mouse models

  Method                       Intracameral injection of microbeads                                                                           Laser photocoagulation of outflow structures                                                                Topical ocular administration of glucocorticoids                     Intracameral injection of silicone oil
  ---------------------------- -------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mechanism                    Blocking aqueous outflow by physically occulding the TM and Schlemm's canal at the angle of anterior chamber   Blocking aqueous outflow by causing photocoagulation damages of the TM, limbal plexus or episcleral veins   Not well established although may be associatd with TM dysfunction   Blocking aqueous inflow by pupillary occulsion, may also decrease aqueous outflow by closure of anterior chamber angel secondary to aqueous accumulation in the back of the eye
  Type of glaucoma             Angle closure; chronic                                                                                         Angle closure; acute                                                                                        Open angle; chronic                                                  Open angle and angle closure; acute
  Repeat of procedure          Multiple repeats                                                                                               Multiple repeats                                                                                            Multiple-repeats                                                     Once
  Reversibility of procedure   No                                                                                                             No                                                                                                          Not sure                                                             Yes
  Effect of procedure          Not obvious, rely on IOP measurement                                                                           Not obvious, rely on IOP measurement                                                                        Not obvious, rely on IOP measurement                                 Visible SO bubble
  IOP elevation                15 mmHg                                                                                                        6--24 mmHg                                                                                                  3--12 mmHg                                                           8--26 mmHg
  Pattern of IOP elevation     Variable                                                                                                       Variable                                                                                                    Stable                                                               Stable
  RGC loss                     Modest                                                                                                         Severe                                                                                                      Modest                                                               Severe
  ON axon loss                 Modest                                                                                                         Severe                                                                                                      Modest                                                               Severe
  Major drawbacks              Variable; modest neurodegeneration                                                                             Severe and irriversible ocular and retinal damages; technical challgenges                                   Systemic effects; labor intensive                                    IOP elevation is only detected after pupil dilation, the IOP may be much higher at the back of the eye

IOP: Intraocular pressure; ON: optic nerve; RGC: retinal ganglion cell; SO: silicone oil; TM: trabecular meshwork.

Like every other model, the SO model also has limitations and complications. An important disadvantage is that the increased IOP can only be detected after dilation removes the pupillary block and aqueous inflow is restored. The SO droplet touching the surface of the iris in combination with the large mouse lens forms a rigid barrier that seals the pupil and essentially disconnects anterior chamber from posterior segment. This seal acts as a dam that keeps IOP low in the anterior segment and high in the posterior segment where the aqueous accumulates. Unfortunately, posterior IOP cannot be measured directly, at least in mouse eyes. Only when the mouse pupil is sufficiently dilated that it is no longer covered by the SO droplet are the anterior and posterior chambers reconnected and the aqueous permitted to quickly flood into the anterior chamber. This flow exceeds outflow from the TM allowing increased IOP in the anterior chamber to be detected. This may also be the reason for another disadvantage of the SO model, which is that the IOP elevation is acute instead of chronic. Thus, this model replicates secondary acute glaucoma in the clinic but not the majority of chronic glaucoma patients. However, the SO model can be modified to be milder and more chronic by more frequent pupil dilation because every dilation releases the aqueous accumulated at the back of the eye and serves as treatment to lower IOP. Although very rare, corneal opacity caused by band-shaped degeneration or neovascularization can occur, which may be associated with the interaction of excessive SO with the endothelial cells of the cornea.

In summary, a simple but effective ocular hypertension model in mice is important for investigating glaucomatous neurodegeneration and testing treatments for neuroprotection. Thus, we resolved to develop a straightforward mouse ocular hypertension model that closely mimics SO-induced secondary glaucoma observed in human patients. The procedure is simple, the IOP elevation is stable, and the neurodegeneration associated with ocular hypertension is severe. Importantly, the ocular hypertension is reversible because the SO can be easily removed. No special equipment or repeated procedures is required. We predict it will expedite selection of neuroprotectants and facilitate establishing the pathogenesis of acute ocular hypertension-induced glaucoma. But the value and shortcomings of this model will become clear only after it is analyzed by more investigators.
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